Novartis cuts 500 traditional roles for 350 ‘high-tech’ ones

pharmafile | May 22, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Novartis 

Novartis has announced a restructure within the company which will lead to the transfer or loss of 500 traditional production and development roles at its Swiss sites as it looks to add 350 others in high tech areas including “development and innovative biologics manufacturing”.

Part of its wider global restructuring efforts, the move is the biggest of its kind planned by the company through to the end of 2018, though smaller reshuffles could not be ruled out. The company stated that these actions illustrated their commitment to manufacturing in Switzerland – its native country. It will lead to around 150 jobs losses which it notes are part of plans launched last year to harmonise operations and “lead to personnel adjustments in various countries”.   

The plan is due to take place over 18 months and will see the closure of production sites in Basel, including the facility at the Schweizerhalle industrial complex. It is thought that some operational capacity may be relocated to India.

Advertisement

Novartis employs approximately 120,000 staff worldwide. In October last year, the company announced it was axing 175 roles related to its research programmes in Switzerland and China as part of a cost-cutting effort to centralise its drug discovery ventures.

Matt Fellows

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content